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832Advisory statement on clinical use of modiﬁed
aortic endografts from the Society for Vascular
Surgery
Rodney A. White, MD, Torrance, CalifRecent enthusiasm to extend the application of aortic
endografts has led to the development of new techniques
that require modiﬁcation of approved endografts to accom-
modate anatomic variations. For the purposes of this
report, a modiﬁed aortic endograft is deﬁned as a physical
modiﬁcation of an existing approved device (including
the implant or deployment system) in such a way that its
potential risks and beneﬁts cannot be extrapolated from
the United States Food and Drug Administration (FDA)-
approved studies upon which the approval of the original
unmodiﬁed commercial device was based. Examples of
such modiﬁcation include surgeon-constructed fenestra-
tions and side branches.
All aortic endografts are deﬁned by federal law as
signiﬁcant-risk devices, and regulations for their use are
enforced by the FDA. Accordingly, clinical studies using
modiﬁed aortic endografts must comply with these regula-
tions to ensure patient safety and accurate reporting of
clinical outcomes.
Currently, there are two mechanisms to conduct
FDA-approved clinical studies of signiﬁcant risk devices:
manufacturer-sponsored or investigator-sponsored Investi-
gational Device Exemptions (IDEs). To get FDA approval
to market an endovascular graft, manufacturers must submit
a Premarket Approval (PMA) application that provides
a reasonable assurance of safety and effectiveness using valid
scientiﬁc evidence. PMA approval usually includes require-
ments for training programs and postmarket follow-up
programs to provide surveillance after introduction.
Investigator-sponsored IDEs enable investigational device
evaluation using the same criteria for scientiﬁc justiﬁcation
and study conduct but are generally not intended to support
a device marketing application or to address training.
As outlined in the Federal Food,Drug, andCosmetic Act
and interpreted in the Federal Register and the Code of
Federal Regulations that codiﬁes the rules published in the
Federal Register, the medical device law and regulations
apply equally to manufacturers and investigators conductingthe David Geffen UCLA School of Medicine, University of California,
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when new devices or modiﬁcation of devices are studied.
If signiﬁcant-risk devices or modiﬁcations of signiﬁcant-
risk devices are used in clinical studies, Institutional Review
Board (IRB) and IDE approval are required. For modiﬁed
aortic endografts, IRB approval alone is not adequate
because the FDA has determined that all aortic endovascular
graft studies are signiﬁcant-risk studies.
This requirement has implications on the investigator and
institutional responsibilities, the patient consent, conduct of
the study, collection of data, reimbursement for procedures,
and reporting to the IRB and the FDA. Scientiﬁc presenta-
tions and publications must clearly delineate the nature of
the study, method of approval, and mechanism to assess
outcomes of interventions. To date, the Center for Medicare
& Medicaid Services has identiﬁed endografts as nonexperi-
mental/investigational devices and is more likely to reimburse
for studies that are conducted in an approved IDE protocol.
HOW DO THESE REGULATORY REQUIRE-
MENTS TRANSLATE TO FREQUENTLY ASKED
CLINICAL QUESTIONS?
Question: In an emergency, can an off-label modiﬁed
endograft be used without additional requirements?
Yes, a physician has the discretion to recommend any
treatment if it is judged to be in the patient’s best interest.
Compassionate-use approvals can also be used for planned
novel treatment of conditions not amenable to conven-
tional treatment. Compassionate use requires IRB approval
and, in addition, may require FDA and manufacturer
approval. Serial planned use of modiﬁed endografts is not
compassionate use. If serial use is planned, IRB and IDE
approvals are required. Local IRBs have different rules,
and some require that elective one-time compassionate
use be approved by an IRB chair using the expedited route,
but if that chair is uncomfortable with making the decision,
it can be sent for full IRB review. Clinical studies of modi-
ﬁed aortic endografts must have IRB and IDE approval.
Refer to:
http://www.fda.gov/MedicalDevices/DeviceRegulation
andGuidance/HowtoMarketYourDevice/Investigational
DeviceExemptionIDE/ucm051345.htm
http://www.fda.gov/MedicalDevices/DeviceRegulation
andGuidance/HowtoMarketYourDevice/Investigational
DeviceExemptionsIDE/umc051345.htm#emergencyuse
Question: How does one consent a patient for modi-
ﬁcation of a commercial endograft?
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a study that has been approved by an IRB and the FDA to
determine the safety and effectiveness of these devices. The
IRB and the FDA both review the draft informed consent
forms to ensure that the study patients are appropriately
informed of their rights, safety, and welfare.
Question: Can an IRB grant approval to perform
modiﬁcation of an aortic endograft without requiring
FDA approval?
The IRB can only grant approval and not require FDA
approval if it believes a study is not a signiﬁcant-risk study.
As mentioned, because all aortic endovascular graft studies
using modiﬁcations of approved devices are signiﬁcant-risk
studies, IRB and FDA approval are both required before
elective modiﬁcation and use of a device.
Question: How can I train for a new unapproved
modiﬁcation of an aortic endograft procedure?
Until the safety and effectiveness of each type of
endograft device modiﬁcation is conﬁrmed, training is
not recommended. Training in the context of an approved
fellowship in an institution that has an approved IDE is
acceptable.
Question: Can presentations at meetings and publica-
tion of papers describing novel modiﬁed aortic endografttreatments be made if patients were treated outside of an
approved IDE?
Presentations of one-time emergency use or compas-
sionate use are acceptable. If a report of a clinical series is
prepared, the IRB and IDE approval status should be
clearly described.
Question: How do I apply for an IDE if I want to
prospectively treat patients with complex anatomy using
modiﬁed commercially available aortic endografts devices?
Contact your IRB and ask how to prepare a submission
to evaluate the risk of your proposed study and how to
prepare an IDE.
Further information is available at:
http://www.fda.gov/MedicalDevices/DeviceRegulation
andGuidance/HowtoMarketYourDevice/Investigational
DeviceExemptionIDE/ucm046706.htm
For speciﬁc information regarding these questions,
refer to
http://www.fda.gov/MedicalDevices/DeviceRegulationand
Guidance/HowtoMarketYourDevice/InvestigationalDevice
ExemptionIDE/default.htmSubmitted Oct 12, 2012; accepted Dec 22, 2012.
